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Introduction: Single agent chemotherapy is standard for second
and third line treatment of non-small cell lung cancer (NSCLC).
Combination therapy to date has not proven to be superior to single
agents in this setting, often adding toxicity without any additional
efficacy. We investigated the activity and tolerability of the combi-
nation of oxaliplatin, pemetrexed, and bevacizumab in patients with
previously treated advanced NSCLC.
Methods: This multicenter phase II trial evaluated the safety and
efficacy of the combination of pemetrexed (500 mg/m2), oxaliplatin
(120 mg/m2), and bevacizumab (15 mg/kg), given every 21 days, in
patients with previously treated advanced NSCLC. Eligibility crite-
ria included performance status 0 to 1, nonsquamous histology, and
at least one prior chemotherapy regimen. Patients with treated brain
metastases were allowed. The primary end point was response rate,
with secondary endpoints of progression-free survival and overall
survival.
Results: Thirty-six patients were enrolled on this study. Treatment
was well tolerated; the most common grade 3 toxicity was hyper-
tension, which was easily managed with oral medications. The nine
(25%) patients with treated brain metastases had no episodes of
cerebral hemorrhage. Of the 34 patients evaluable for tumor re-
sponse, none had complete response, nine (27%) had partial re-
sponse, 15 (44%) had stable disease, and 10 (29%) had progressive
disease. Median progression-free survival was 5.8 months (95%
confidence interval 4.1–7.8 months) and median overall survival
was 12.5 months (95% confidence interval 7.3–17 months).
Conclusions: Treatment with oxaliplatin and pemetrexed in com-
bination with the targeted antiangiogenic agent bevacizumab yielded
promising efficacy with manageable toxicity in the previously
treated advanced NSCLC population.
Key Words: Non-small cell lung cancer, Oxaliplatin, Pemetrexed,
Bevacizumab, Previously treated.
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Lung cancer is the leading cause of cancer-related death inthe United States.1 Most patients with non-small cell lung
cancer (NSCLC) are diagnosed with advanced disease, and
platinum-based chemotherapy regimens are the backbone of
first-line treatment.2 Bevacizumab, a monoclonal antibody to
vascular endothelial growth factor, is the first molecularly
targeted treatment to show benefit when added to first-line
chemotherapy for NSCLC, improving median survival from
10 to 12 months.3 Early-phase clinical trials suggest that
bevacizumab may also add benefit when combined with
second-line therapies for NSCLC.4
Despite these advances, the prognosis for patients with
advanced NSCLC is limited and virtually all patients will
progress. Finding better second and third-line therapies is
critical to improving survival. Currently, docetaxel, pem-
etrexed, and erlotinib are approved for second-line treatment
of NSCLC. Response rates for these agents in large phase III
trials are generally less than 10%, with progression-free
survival (PFS) that ranges from 2 to 3 months, and median
overall survival (OS) of 6 to 8 months.5–8
Although combination chemotherapy is standard for
first-line treatment, in previously treated patients combination
therapy to date has had no clear benefit over single agents,
often adding toxicity without additional efficacy. However,
many of these studies were performed with older chemother-
apeutics. More modern regimens are worth exploring, espe-
cially if they are thought to render better response rates and
survival, or to combine more easily into multidrug regimens
with tolerable side effects.
The combination of oxaliplatin and pemetrexed has
been of particular interest because it has demonstrated both
good efficacy and a tolerable side effect profile. Although it
is a member of the platinum family, oxaliplatin has activity in
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cisplatin-resistant cell lines.9 More importantly, clinical stud-
ies have confirmed that oxaliplatin retains activity in individ-
uals previously treated with cisplatin or carboplatin.10,11 The
combination of oxaliplatin and pemetrexed was compared
with carboplatin and pemetrexed as first-line therapy for
NSCLC in a randomized phase II study.12 Response rates
were 27 and 33%, respectively, and not statistically different.
Toxicity in the oxaliplatin/pemetrexed arm was quite low,
suggesting that this is a tolerable combination with potential
efficacy in a population previously exposed to platinum.
We investigated the activity and safety of the regimen
of bevacizumab, oxaliplatin, and pemetrexed in the previ-
ously treated advanced NSCLC setting with the hope that the
favorable profile of oxaliplatin with pemetrexed in platinum-
treated patients and the antiangiogenic activity of bevaci-
zumab would combine to yield a powerful yet manageable
regimen. We elected to include patients with definitively
treated brain metastases in this study. The presence of any
brain metastasis was an exclusion criteria in Eastern Coop-
erative Oncology Group (ECOG) 4599, the randomized
phase III trial that compared chemotherapy alone with che-
motherapy with bevacizumab in the first-line setting.2 How-
ever, a substantial proportion of patients with advanced
NSCLC have brain metastases. Furthermore, studies in pa-
tients with malignant glioma suggest that bevacizumab can be
given safely to patients with brain tumors.13 Therefore, to
study this regimen in a typical population of patients with
advanced relapsed and refractory NSCLC, we included pa-
tients with stable and fully treated brain metastases.
PATIENTS AND METHODS
Patients/Eligibility
Eligibility criteria included stage IIIB (by pleural or
pericardial effusion), stage IV, or recurrent NSCLC,
nonsquamous histology, age 18 years, ECOG performance
status of 0 to 1, life expectancy 12 weeks, measurable
disease by Response Evaluation Criteria in Solid Tumors
(RECIST), at least one prior chemotherapy regimen, and
adequate bone marrow, renal and hepatic function. Patients
were not eligible if there was a history of bleeding diathesis
or coagulopathy, arterial thrombotic event such as myocardial
infarction or stroke in the previous 6 months, gross hemop-
tysis within the prior 4 weeks, major surgical procedures in
the previous 4 weeks, minor surgical procedures in the
previous 7 days, serious nonhealing wound, ulcer, or bone
fracture, or history of abdominal fistula, gastrointestinal per-
foration, or intraabdominal abscess. Patients with current
venous thrombosis, active coronary artery disease with symp-
toms of unstable angina, uncontrolled arrhythmia, uncon-
trolled hypertension, or ongoing infection, were ineligible.
Patients could not have received previous therapy with ox-
aliplatin or pemetrexed. Brain metastases were allowed as
long as they had been treated and were not hemorrhagic.
Treatment Plan
Patients received pemetrexed 500 mg/m2, oxaliplatin
120 mg/m2, and bevacizumab 15 mg/kg on day 1 of every 21
day cycle. A maximum of two dose reductions were allowed
based on nadir counts or clinically significant nonhemato-
logic toxicities. All patients received 1000 micrograms of
vitamin B-12 intramuscularly at least 1 week before the start
of treatment and again every 9 weeks, and folic acid 1 mg
daily starting at least 1 week before therapy and continuing
throughout treatment. Patients were premedicated with dexa-
methasone (4 mg twice daily the day before, the day of, and
the day after chemotherapy). Growth factors were allowed at
the discretion of the treating physician. Tumor measurements
were assessed by means of computed tomography scan or
magnetic resonance imaging using RECIST after every two
cycles. In the absence of progressive disease or unacceptable
toxicity, patients continued on the study drugs for a maxi-
mum of six cycles.
Statistical Analysis
The primary objective was to estimate the response rate of
patients treated with bevacizumab, oxaliplatin, and pemetrexed.
A two-stage phase II design was used, with an interim analysis
and an early stopping rule for inactivity. Sample size was
calculated based on Simon’s method.14 The first stage included
15 patients. If at least two of these patients achieved a partial or
complete response by RECIST, enrollment proceeded with an
additional 20 patients. This design provided a 92% probability of
identifying an active regimen if the true response rate were truly
25%, the level regarded as the minimum to declare the triplet
regimen clinically active. In contrast, there was a 6% probability
of failing to declare the regimen inactive assuming a true
response rate of 5% or less.
Secondary objectives were to assess PFS and OS. OS
was defined as the time from date of registration to date of
TABLE 1. Patient Characteristics
Patient Characteristic n (%)
Median age (range) 62 (40–81)
Male 18 (50%)
Female 18 (50%)
Stage at study entry
IIIB (wet) 2 (6%)
IV 34 (94%)
ECOG PS
0 13 (36%)
1 23 (64%)
Histology
Adenocarcinoma 29 (80%)
BAC 1 (3%)
Large cell 2 (6%)
NSCLC nos 4 (11%)
No. prior regimens
1 24 (66%)
2 7 (19%)
3 2 (6%)
4 2 (6%)
5 1 (3%)
Presence of brain mets
Yes 9 (25%)
No 27 (75%)
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death. PFS was the time from registration until documented
progression or death from any cause, whichever occurred
first. Survival analyses were performed using the Kaplan-
Meier method.
RESULTS
Thirty-six patients were enrolled between January 2005
and October 2006 from four institutions. All patients received
therapy with pemetrexed, oxaliplatin, and bevacizumab. The
median number of cycles received was 5.5; range was 1 to 6.
At the time of analysis, 31 patients had progressed and 29
patients had died. Two patients were not assessable for
response; one patient died and another withdrew from the
study before the first scheduled restaging scans. The median
follow-up for all patients was 11 months, and clinical data
were collected through December 2007.
The baseline patient and clinical characteristics are
listed in Table 1. There were nine patients with treated brain
metastases. All patients had received prior chemotherapy,
with all but two having had a prior platinum-based combina-
tion. There were no patients who had received prior bevaci-
zumab. Details of prior treatment regimens are included in
Table 2.
Efficacy
Thirty-four patients were assessable for response. The
response rate was 27%, with no complete responses, nine
(27%) partial responses, 15 (44%) patients with stable dis-
ease, and 10 (29%) with progressive disease. The median PFS
was 5.8 months (95% confidence interval 4.1–7.8 months);
see Figure 1. The median OS was 12.5 months (95% confi-
dence interval 7.3–17 months); see Figure 2.
Twenty-one (59%) patients received additional thera-
pies after participating in this study. Thirteen (36%) received
one subsequent therapy, six (17%) received two subsequent
therapies, one (3%) received three subsequent therapies, and
one (3%) received four subsequent therapies.
Toxicity
There was one fatal toxicity from hemoptysis. This
occurred in a 56-year-old woman with stage IV NSCLC
(including metastases to brain, liver, adrenal) who had pro-
gressed after whole brain radiotherapy and two cycles of
cisplatin and docetaxel chemotherapy. Her tumor histology
was poorly differentiated non-small cell carcinoma, not oth-
erwise specified. She started second-line therapy on the study
protocol and received two cycles of pemetrexed, oxaliplatin,
and bevacizumab. Two days after receiving cycle 2, she
experienced sudden, massive hemoptysis, and expired at
home. Her primary lung mass was central in the chest,
encasing the left main bronchus and left main pulmonary
artery. There were no tumor cavitations observed in her
baseline scan obtained before the start of treatment.
There were no other grade 4 or 5 toxicities observed.
The most common grade 3 toxicity was hypertension, occur-
ring in six (17%) patients. One patient developed new hyper-
tension during cycle 5 of treatment which resolved with
addition of a beta-blocker. Five patients had known hyper-
tension and were on antihypertensive drugs before start of
therapy, and required an increase in their oral regimen. All
cases of hypertension were manageable with oral medication
adjustment alone. Other grade 2 to 4 toxicities are noted in
Table 3.
DISCUSSION
The standard wisdom in the treatment of advanced
NSCLC in the second-line and third-line setting has been that
combination therapy has no advantage over single agent
therapy, only adding toxicity with little additional efficacy.
The development of novel targeted drugs offers a chance to
re-examine this paradigm and ask if combinations of newer
agents might prove superior.
We have demonstrated in a multi-institution phase II
trial that a combination of oxaliplatin, pemetrexed, and bev-
acizumab administered to previously treated advanced
NSCLC patients is well tolerated and efficacious, with a
response rate of 27%, median PFS of 5.8 months, and median
OS of 12.5 months. Although this single-arm phase II study
is not definitive, our results are provocative and raise hope
that with modern chemotherapeutics and novel targeted
agents, improvement in outcomes with second-line therapies
and beyond may be possible. Table 4 summarizes selected
agents that are commonly used in the second-line setting,
with their associated response rates and survival statistics.
Although most of these trials were randomized phase III trials
and should not be directly compared with our results, it is
TABLE 2. Prior Treatments
One prior regimen
Carboplatin/paclitaxel 9
Carboplatin/paclitaxel/TLK286 8
Carboplatin/gemcitabine 1
Cisplatin/docetaxel 1
Surgery 3 carbo/paclitaxel/RT 1
EP 50/50 with RT-consolidation taxotere 1
Carboplatin/paclitaxel/RT 1
Carboplatin/paclitaxel/RT-consolidation carboplatin/gemcitabine 1
Surgery 3 adjuvant carboplatin/paclitaxel 1
Two prior regimens
Carboplatin/paclitaxel 3 gefitinib/erlotinib 2
Carboplatin/paclitaxel 3 gemcitabine/docetaxel 1
Cisplatin/gemcitabine/LY293111 3 carboplatin/docetaxel 1
Cetuximab/navelbine 3 erlotinib 1
Carbo/paclitaxel/RT–surgery–carbo/paclitaxel 3 erlotinib 1
Surgery-EP 50/50/RT 3 carboplatin/paclitaxel/TLK286 1
Three prior regimens
Carboplatin/paclitaxel 3 docetaxel 3 erlotinib 1
Carboplatin/paclitaxel RT-consolidation cisplatin/gemcitabine
3 erlotinib 3 HKI272
1
Four prior regimens
Gefitinib 3 erlotinib 3 carboplatin/gemcitabine 3 HKI272 1
Carboplatin/gemcitabine 3 docetaxel 3 etoposide 3 erlotinib 1
Five prior regimens
Gemcitabine 3 navelbine/docetaxel 3 cpt-11 3 gefitinib 3
erlotinib
1
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clear that the promising treatment outcomes we obtained with
oxaliplatin, pemetrexed, and bevacizumab in a phase II trial
in this population are worthy of further study.
Treatment with the combination of oxaliplatin, pem-
etrexed, and bevacizumab was well tolerated. The most
common grade 3 toxicity was hypertension, a well-described
FIGURE 1. Progression-free survival.
FIGURE 2. Overall survival.
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class effect of antiangiogenic therapy, which was easily
manageable with standard antihypertensive medications.
There was one fatal pulmonary hemorrhage. Although the
patient did not have squamous cell histology, which was an
exclusion criteria, the primary lung mass was a large central
tumor encasing the major pulmonary vessels. There were no
central nervous system bleeding complications, including the
nine patients who had previously treated brain metastases.
Although central nervous system metastases still remain an
exclusion criteria for the standard use of bevacizumab in
NSCLC, an ongoing phase II trial (known as the PASSPORT
trial) is investigating the safety of bevacizumab in patients
with treated brain metastases in nonsquamous advanced
NSCLC.
The addition of bevacizumab to platinum-based che-
motherapy in the first-line setting is clearly the standard of
care for patients who meet the appropriate eligibility criteria.
ECOG 4599 showed the benefit in OS of bevacizumab added
to carboplatin and paclitaxel in the first-line treatment of
advanced NSCLC.3 Also in the first-line setting, the AVAIL
study randomized patients to cisplatin and gemcitabine, with
or without bevacizumab at dose levels of 7.5 or 15 mg/kg.15
Both the 7.5 and 15 mg/kg dose levels showed an improve-
ment in PFS when compared with chemotherapy alone. Our
study was designed before the results of AVAIL were first
reported, and it is not known whether a 7.5 mg/kg dose would
have yielded similar results in our study.
In addition to treatment in the first-line setting, bevaci-
zumab in the second-line therapy for NSCLC may improve
outcomes. In a recently reported randomized phase II trial,
patients with recurrent or refractory advanced NSCLC were
treated with either chemotherapy (pemetrexed or docetaxel)
alone, or chemotherapy or erlotinib in combination with
bevacizumab.4 Similarly to our study, patients enrolled on
this trial had not received bevacizumab as part of prior
chemotherapy regimens. PFS and OS, although not statisti-
cally significant, favored the bevacizumab arms. Median PFS
was 4.8 and 4.4 months in the bevacizumab with chemother-
apy or erlotinib arms respectively, compared with 3.0 months
in the chemotherapy alone arm. OS also favored the bevaci-
zumab arms, with median OS of 12.6 or 13.7 months in the
bevacizumab with chemotherapy or erlotinib arms, respec-
TABLE 3. Toxicities
Toxicity Grade 2 Grade 3 Grade 4 Grade 5
Neutropenia 3 1 0 0
Febrile neutropenia 0 0 0 0
Anemia 1 1 0 0
Thrombocytopenia 2 1 0 0
Fatigue 11 3 0 0
Nausea 1 1 0 0
Vomiting 1 1 0 0
Dehydration 1 1 0 0
Constipation 5 1 0 0
Abdominal pain 4 1 0 0
Infectious colitis 0 1 0 0
Port infection 0 1 0 0
Face pain 0 1 0 0
Hypertension 0 6 0 0
Neuropathy 3 1 0 0
Elevated ALT/AST 3 1 0 0
Hemoptysis 0 0 0 1
Dyspnea 8 1 0 0
Wheeze/bronchospasm 1 1 0 0
Allergic reaction 0 1 0 0
Pain 4 0 0 0
Depression 1 0 0 0
Dizziness 1 0 0 0
Cough 8 0 0 0
Alopecia 2 0 0 0
Anorexia 2 0 0 0
Rash 1 0 0 0
Fever without neutropenia 1 0 0 0
Headache 2 0 0 0
Hyperglycemia 1 0 0 0
Diarrhea 3 0 0 0
TABLE 4. Therapies for NSCLC in Second Line and Beyond
Drug Phase of Study No. Prior Regimens RR (%) TTP (wk) Median Survival (mo)
Docetaxel5 III 1 7.1 10.6 7.0
Best supportive care 6.7 4.6
Docetaxel 100 mg/m2 III 1 10.8 8.4 5.5
Docetaxel 75 mg/m2 6.7 8.5 5.7
Vinorelbine/ifosfamide 0.8 7.9 5.6
PFS (mo)
Pemetrexed7 III 1 9.1 2.9 8.3
Docetaxel 8.8 2.9 7.9
Erlotinib8 III 2 8.9 2.2 6.7
Placebo 1 1.8 4.7
Chemotherapya  placebo4 Randomized II 1 12.2 3.0 8.6
Chemotherapya  bevacizumab 12.5 4.8 12.6
Erlotinib  bevacizumab 17.9 4.4 13.7
a Pemetrexed/docetaxel.
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tively, compared with 8.6 months in the chemotherapy alone
arm. Response rates were 12.5% with chemotherapy and
bevacizumab and 17.9% with erlotinib and bevacizumab.
Interestingly, a recently reported phase III trial showed
in a prespecified subset analysis that patients with adenocar-
cinoma or large cell histology may derive more benefit from
pemetrexed in combination with cisplatin in the first-line
setting.16 As squamous histology was an exclusion criteria in
our trial, most of our patients had either adenocarcinoma or
large cell histology, and may be a subset of patients who
might be expected to do well with pemetrexed.
In conclusion, treatment with a chemotherapy regimen
of oxaliplatin and pemetrexed in combination with the tar-
geted antiangiogenic agent bevacizumab yielded promising
efficacy results with manageable toxicity in previously
treated advanced NSCLC patients. Our results suggest that
aggressive treatment of fit patients in the second-line setting
and beyond could improve outcomes, and this regimen
should be investigated in further trials. A randomized trial
comparing oxaliplatin, pemetrexed, and bevacizumab to pem-
etrexed and bevacizumab would be warranted to further
investigate the comparative benefit of this combination.
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